HER2+ Cancers

This page is the deeper mechanism page behind the shorter question page on whether HER2+/ERα+ patients should avoid resveratrol or polydatin.

If you want the practical answer first, start here:

• Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?

This page goes deeper into why the caution exists, where the evidence comes from, and where its limits begin.

Short answer first

The current concern is strongest in HER2-positive breast cancer, not in all HER2-positive cancers generally.

More specifically, it is strongest in HER2-positive, ER-positive breast cancer where Luminal B-like or triple-positive biology may overlap with the Δ16HER2 / resveratrol signal.

That is why this page should be read as a breast-cancer-specific caution page, not a blanket HER2-wide rule.

What is Δ16HER2?

Δ16HER2 is an oncogenic splice variant of HER2. It is not the same as routine HER2 overexpression alone.

It has been described especially in breast cancer, where it has been linked to aggressive behaviour and trastuzumab resistance.

Why it matters for polydatin

Polydatin is metabolised toward resveratrol.

The caution comes from evidence that resveratrol accelerated tumour growth in a Δ16HER2 transgenic breast-cancer mouse model rather than inhibiting it.

That matters because polydatin is not a separate universe from resveratrol.

It is a related compound with its own biology, but it also feeds into the resveratrol story through metabolism.

That means the concern is not a generic statement that polydatin is unsafe in every HER2-positive cancer.

It is a specific mechanistic warning that becomes most relevant when discussing HER2-positive breast cancer, especially when ERα signalling is still active and Δ16HER2 biology may be present.

What this page adds beyond the shorter HER2+ answer page

The shorter page gives the clean practical conclusion.

This page adds three things:

• the Δ16HER2 background

• the reason the warning is breast-cancer-specific

• the limits of the evidence, so the caution is not overstated

For the wider breast-cancer evidence on polydatin itself, also see Breast Cancer.

What we can and cannot say honestly

What we can say

• There is a real peer-reviewed signal of concern in a Δ16HER2 breast-cancer model

• Because polydatin converts toward resveratrol, this deserves clinician review in HER2-positive breast cancer

• The concern is important enough that it should not be buried or dismissed

What we cannot say confidently

• We cannot say this applies to all HER2-positive cancers

• We cannot say every HER2-positive tumour has clinically relevant Δ16HER2 expression

• We cannot say this has been confirmed in human oncology trials

Practical interpretation for readers

For readers with HER2-positive breast cancer, polydatin should not be treated as a casual self-directed adjunct.

The combination of:

• possible direct mechanistic benefits from polydatin

• possible cardioprotective rationale in some treatment settings

• and the unresolved Δ16HER2 / resveratrol concern

means this belongs in a discussion with the treating oncologist.

For readers who arrived here from the shorter question page, this is the main reason that page lands on "discuss first" rather than offering quick reassurance.

For other HER2-positive cancers, the evidence is not strong enough to automatically extend the same warning without saying clearly that the current Δ16HER2 concern is mainly breast cancer-based.

This is best framed as a HER2-positive breast cancer caution, not a blanket HER2-wide rule.

If you want the deeper paper-level breakdown, use the expandable section below.

Related pages

• Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin? — short practical answer

• Breast Cancer — wider polydatin breast-cancer evidence

• Triple-Positive — overlap between HER2 and hormone-receptor biology

• Distinguishing Luminal A from Luminal B — subtype context for this caution

References

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as an oncogenic compound in Δ16HER2 transgenic mice — Andreani, Bartolacci et al., Aging, 2017
https://pmc.ncbi.nlm.nih.gov/articles/PMC5361678/

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers — comprehensive review, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Cancers, 2019
https://pmc.ncbi.nlm.nih.gov/articles/PMC6678616/

HER2 isoforms co-expression differently tunes mammary tumour phenotypes — companion paper from same research tradition, PMC, 2017
https://pmc.ncbi.nlm.nih.gov/articles/PMC5589593/

Combination treatment with PI3K/AKT/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer
https://pubmed.ncbi.nlm.nih.gov/33303839/